Clinical Utility of Fecal Neutrophil Gelatinase-Associated Lipocalin and Calprotectin as Biomarkers of Clostridioides (Clostridium) difficile Infection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Current methods for diagnosing Clostridioides difficile infections (CDIs) fail to provide information on their severity. Fecal neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin are candidate biomarkers for evaluating the severity of intestinal inflammation. We assessed fecal NGAL and calprotectin levels in patients with CDI and compared these values between subgroups of patients. We also evaluated their utility in predicting CDI clinical outcomes. Methods: A total of 147 leftover fecal samples were obtained; 97 samples were from patients with CDI and 50 were from routine healthcare checkups. Fecal calprotectin and NGAL levels were measured using a Quantitative Fecal NGAL ELISA Kit and Quantitative Fecal Calprotectin ELISA Kit (Epitope Diagnostics, USA). Results: Significant differences in fecal NGAL and calprotectin levels were observed between CDI patients and healthy controls (P
Abstract
Background: Current methods for diagnosing Clostridioides difficile infections (CDIs) fail to provide information on their severity. Fecal neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin are candidate biomarkers for evaluating the severity of intestinal inflammation. We assessed fecal NGAL and calprotectin levels in patients with CDI and compared these values between subgroups of patients. We also evaluated their utility in predicting CDI clinical outcomes. Methods: A total of 147 leftover fecal samples were obtained; 97 samples were from patients with CDI and 50 were from routine healthcare checkups. Fecal calprotectin and NGAL levels were measured using a Quantitative Fecal NGAL ELISA Kit and Quantitative Fecal Calprotectin ELISA Kit (Epitope Diagnostics, USA). Results: Significant differences in fecal NGAL and calprotectin levels were observed between CDI patients and healthy controls (P
참고문헌 (28)
- Lawson PA, "Reclassification of Clostridium difficile as Clostridioides difficile(Hall and O’Toole 1935)Prévot 1938", Anaerobe, 40, pp.95~99 (2016)
- Balsells E, "Global burden of Clostridium difficile infections: a systematic review and meta-analysis", J Glob Health, 9, pp.010407~ (2019)
- McDonald LC, "Clinical practice guidelines for Clostridium difficile infection in adults and children : 2017 Update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA)", Clin Infect Dis, 66, pp.987~994 (2018)
- Senchyna F, "Clostridium difficile PCR cycle threshold predicts free toxin", J Clin Microbiol, 55, pp.2651~2660 (2017)
- Manceau H, "Fecal calprotectin in inflammatory bowel diseases : update and perspectives", Clin Chem Lab Med, 55, pp.474~483 (2017)
- Thorsvik S, "Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease", J Gastroenterol Hepatol, 32, pp.128~135 (2017)
- Budzynska A, "Serum neutrophil gelatinase-associated lipocalin(NGAL)correlates with clinical and endoscopic activity in ulcerative colitis but fails to predict activity in Crohn’s disease", J Physiol Pharmacol, 68, pp.859~865 (2017)
- Foster AJ, "Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients", World J Gastroenterol, 25, pp.1266~1277 (2019)
- Barbut F, "Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection : a case–control study", Eur J Clin Microbiol Infect Dis, 36, pp.2423~2430 (2017)
- Swale A, "Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection(CDI) : A prospective cohort study", PLoS One, 9, pp.e106118~ (2014)
- Wright EK, "Calprotectin or lactoferrin : Do they help", Dig Dis, 34, pp.98~104 (2016)
- Debast SB, "European Society of Clinical Microbiology and Infectious Diseases : update of the treatment guidance document for Clostridium difficile infection", Clin Microbiol Infect, 20, pp.1~26 (2014)
- "Quantitative fecal calprotectin ELISA kit"[URL]
- "Human fecal NGAL (LCN2) ELISA kit"[URL]
- Sipponen T, "Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease", Scand J Gastroenterol, 50, pp.74~80 (2015)
- Singer E, "Neutrophil gelatinase-associated lipocalin : pathophysiology and clinical applications", Acta Physiol(Oxf), 207, pp.663~672 (2013)
- Nakashige TG, "Human calprotectin is an iron-sequestering host-defense protein", Nat Chem Biol, 11, pp.765~771 (2015)
- Zhang A, "Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis : a systematic review and meta-analysis", Crit Care, 20, pp.41~ (2016)
- D’Angelo F, "Calprotectin in daily practice : Where do we stand in 2017", Digestion, 95, pp.293~301 (2017)
- He T, "Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection", Eur J Clin Microbiol Infect Dis, 37, pp.2341~2346 (2018)
- Rao K, "Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults", Infect Dis(Lond), 48, pp.663~669 (2016)
- Cho SY, "To the editor : Molecular epidemiology of toxigenic Clostridium difficile isolates in Korea", Epidemiol Infect, 142, pp.1651~1652 (2014)
- Davies KA, "Underdiagnosis of Clostridium difficile across Europe : the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea(EUCLID)", Lancet Infect Dis, 14, pp.1208~1219 (2014)
- Valiente E, "The Clostridium difficile PCR ribotype 027 lineage : a pathogen on the move", Clin Microbiol Infect, 20, pp.396~404 (2014)
- Gallo A, "Fecal calprotectin in management of Clostridium difficile infection : a longitudinal study", Scand J Gastroenterol, 53, pp.567~572 (2018)
- Popiel KY, "Usefulness of adjunctive fecal calprotectin and serum procalcitonin in individuals positive for Clostridium difficile toxin gene by PCR assay", J Clin Microbiol, 53, pp.3667~3669 (2015)
- Peretz A, "Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection", BMC Infect Dis, 16, pp.309~ (2016)
- "difficile"[URL]